spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Norwich Pharmaceuticals Announces Significant Business Growth

Norwich Clinical Services

Increased project volume, new clients propel revenues and expanded services

Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has achieved significant business growth in first quarter, 2012 as compared to the same period in 2011. Key growth areas include volume of projects currently in development and commercial production, scope of projects expanded into multiple service categories, and total value of new business won.

"Norwich’s growth is a direct result of our ability to maintain high quality standards while providing expertise and flexibility for both product development and commercial manufacturing," said Terry Novak, president of Norwich. "During the past year, Norwich has expanded our capabilities to meet the market demands for smaller scale development services. Providing expertise in novel, solid dose formulations, we have been able to offer services to new clientele while increasing our repeat business rate with current customers."

New client awards in the first quarter accounted for 33% of all Norwich projects while repeat business in Q1, 2012 more than doubled as compared to the same period last year. The total value of new projects increased 25%. Several of the new projects will utilize Norwich services for potent compounds, low humidity, bead extrusion, tablet coating, formulation development, BA/BE studies, and global packaging and distribution.

About Norwich Pharmaceuticals

Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for more information.

phone +1 888 674 7979
email info@norwichpharma.com
web www.norwichpharma.com
email 6826 State Highway 12, Norwich, NY 13815, UNITED STATES
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Goodwin Biotechnology Announces the Completion of cGMP Manufacturing of an IgM Monoclonal Antibody and IgM-Ligand Conjugate for Q Therapeutics, and Successful Clearance of Q Therapeutics’ IND Submission for Q‐Cells® Cell Therapy in ALS

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization (CDMO) that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, has partnered with Q Therapeutics, Inc., a clinical‐stage developer of novel cellular therapies for central nervous system (CNS) diseases to provide GMP antibodies for manufacture of clinical trial materials.
More info >>


White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

Industry Events

MAGHREB PHARMA Expo

29 September - 1 October 2015, Hilton Hotel, Algiers (Algeria)

MAGHREB PHARMA Expo is the largest pharmaceutical technology tradeshow in Africa
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement